Progesterone-receptor negative breast cancer

This phase 1 trial tests an investigational DNA vaccine called pING-hHER3FL in people whose solid tumors have been surgically removed. The vaccine carries the genetic code for the HER3 protein, which is found on many cancer types, and aims to trigger a targeted immune response ag…

This study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…

This phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…

This early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…

This phase III trial tests whether a smartphone app called Quit2Heal can help cancer patients stop smoking better than the standard QuitGuide app. The study involves 427 adults with cancer who smoke and are interested in quitting. Participants use one of the two apps to get suppo…

This early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…

This early-phase trial tests two different drug combinations—olaparib plus vistusertib, or olaparib plus capivasertib—in people with recurrent endometrial, triple-negative breast, ovarian, primary peritoneal, or fallopian tube cancer. The main goal is to find the safest dose and …

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…

This early trial tests a radioactive drug called MNPR-101-PCTA-177Lu in adults with advanced solid tumors, including bladder, breast, lung, and pancreatic cancers. Participants receive three equal doses by IV over two 12-week cycles. The main goal is to find a safe dose and under…

This study tests an experimental drug called LM-108, given alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see …

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This early-phase trial is testing a gel form of the drug endoxifen, applied to the skin, in 32 women scheduled for breast surgery. The goal is to see if the gel is safe and how much of the drug gets into breast tissue and blood. If successful, it might offer a gentler way to trea…

This early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions wor…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This phase 1 trial tests FF-10832, a liposomal version of the chemotherapy drug gemcitabine, in adults with advanced solid tumors, including biliary tract cancer, that have not responded to standard treatment or have no standard options. Researchers give the drug as an intravenou…

This early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This phase 1 trial tests whether combining several investigational immunotherapy drugs, with or without chemotherapy, can safely shrink advanced solid tumors. The study enrolls adults with cancers like non-small-cell lung cancer or triple-negative breast cancer that have progress…

This phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…

This study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…

This study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and a…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This trial tests an experimental drug called CS5001, designed to seek out and destroy cancer cells that carry a specific marker (ROR1). It is being studied in people with advanced solid tumors or lymphomas that have progressed after standard treatments. The study will first find …

This early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants wil…

This study tests a new drug, DS-1062a, in people with advanced solid tumors like lung and breast cancer that haven't responded to other treatments. It's the first time this drug is being used in humans, so the main goals are to check safety, find the right dose, and see if it hel…

This study tests a new drug called Dato-DXd in Chinese patients with advanced non-small-cell lung cancer or triple-negative breast cancer that has spread or stopped responding to treatment. The drug targets and kills cancer cells by attaching to them and blocking growth. About 11…

This study tests a clinic program called ActivityChoice that helps cancer survivors become more physically active to lower their risk of heart disease. About 114 adult cancer survivors will be offered a choice of group in-person, group virtual, or self-monitored digital exercise …

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…

This phase III trial tests whether adding pembrolizumab (Keytruda) after standard chemotherapy can help prevent triple-negative breast cancer from coming back. Over 1,100 patients with residual cancer after chemo are randomly assigned to receive pembrolizumab or placebo. The stud…

This study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …

This early-phase trial is testing whether giving two drugs—lenvatinib and pembrolizumab—before surgery can boost the immune response in people with early-stage triple-negative breast cancer. Only 12 participants will receive the short treatment before their planned surgery. The m…

This early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…

This early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …

This early-stage trial tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. It is a firs…

This study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…

This early-stage trial is testing a drug called dostarlimab in 730 people with advanced solid tumors that have not responded to other treatments. Dostarlimab works by helping the immune system recognize and attack cancer cells. The study is checking for safe doses and any side ef…

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This early-stage trial is testing an experimental drug called IBI363 in people with advanced solid tumors or lymphoma that have progressed despite standard treatment. IBI363 is designed to boost the immune system in two ways: by stimulating immune cells with an IL-2-like signal a…

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…

This early-stage study tests two drugs, palbociclib and avelumab, together for people with a specific type of advanced breast cancer (AR+ triple negative). The main goals are to find the safest doses and see if the combination can shrink tumors. About 45 participants will take pa…

This phase II trial is testing a combination of four drugs—trilaciclib, pembrolizumab, gemcitabine, and carboplatin—in people with advanced triple-negative breast cancer that cannot be removed by surgery or has spread. The study aims to see how well the treatment works and how sa…

This study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow thei…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This trial is testing whether combining chemotherapy with two immunotherapy drugs, given before surgery, can completely eliminate triple-negative breast cancer in people with stage II-III disease. Participants will receive six cycles of the combination, and the main goal is to se…

This phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…

This trial tests whether personalized nutrition counseling to increase fiber intake can help preserve the diversity of gut microbes in people undergoing treatment for early-stage triple-negative breast cancer. Participants are randomly assigned to receive either coaching from a r…

This early-stage trial tests a new drug called CHS-114, alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body handles th…

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…

This early-stage trial is testing an experimental pill called SIM0532 in adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, to find a safe dose, and then to see if the drug can shrink tumors or slow their gr…

This study offers ongoing treatment with the cancer drug durvalumab to people who have already completed a previous study and are still benefiting from the drug, as decided by their doctor. The main goal is to monitor safety and side effects. About 214 participants will be enroll…

This trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…

This early-stage trial is testing an experimental drug called JS107 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see how well the body tolerates JS107 when given alone or combined wit…

This trial tests whether giving the immunotherapy drug durvalumab before surgery can help women with early, small triple negative breast cancer. Participants receive two infusions of durvalumab, then either proceed to surgery or, if needed, additional standard therapy. The study …

This early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…

This study tests whether combining the immunotherapy drug durvalumab with other cancer treatments (with or without chemotherapy) can help control metastatic triple negative breast cancer in people who have not had prior treatment for advanced disease. About 243 women with advance…

This early-stage study tests two drugs, veliparib and dinaciclib, in adults with advanced solid tumors that have spread and cannot be cured. The goal is to find the safest dose and understand side effects. About 121 participants will take part to see if this combination can slow …

This study tests a drug called trastuzumab deruxtecan (T-DXd) combined with other anti-cancer medicines in people with metastatic HER2-low breast cancer. The goal is to find safe doses and see if the combination can shrink tumors or slow the cancer's growth. About 138 adults with…

This early-stage trial tests a drug called berzosertib combined with radiation therapy for people with certain types of breast cancer that no longer respond to chemotherapy. The goal is to find the safest dose and see if the combination can shrink or stabilize tumors better than …

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…

This trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …

This phase 3 trial is testing whether adding an experimental immunotherapy drug called PM8002 to standard chemotherapy (nab-paclitaxel) can help people with advanced triple-negative breast cancer live longer without their disease worsening. The study enrolls women aged 18 to 70 w…

This study follows patients with advanced solid tumors who are already benefiting from the cancer drug spartalizumab (PDR001). The goal is to continue monitoring safety and side effects while allowing patients to keep receiving the treatment. About 120 participants are enrolled f…

This study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…

This study is for people with advanced or metastatic cancer who have already been taking futibatinib in a previous study and are still benefiting from it. The goal is to keep giving them the drug (alone or with fulvestrant) and watch for any side effects over a longer period. Onl…

This phase 2 trial is testing whether adding the immunotherapy drug cemiplimab (Libtayo) to standard chemotherapy can eliminate more cancer before surgery in people with high-risk or locally advanced breast cancer. The study enrolls 36 participants with either hormone receptor-po…

This study is testing whether adding an immune-boosting drug (BDB001) and targeted radiation to the immunotherapy atezolizumab can help control or shrink tumors in people with advanced solid tumors, including pancreatic, lung, bladder, and breast cancers. About 247 adults with th…

This study offers continued treatment with atezolizumab (Tecentriq) to about 1,000 cancer patients who were already benefiting from it in earlier Roche-sponsored trials. Participants may also receive other drugs like bevacizumab or alectinib. The main goal is to provide ongoing a…

This early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…

This trial tests an experimental drug called ST316, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study focuses on tumors that may have abnormalities in a cell signaling pathway called WNT/β-catenin. The…

This study tests a drug called sacituzumab govitecan (Trodelvy) in people with advanced triple-negative breast cancer that has worsened after chemotherapy. The goal is to see how well the drug shrinks tumors and to find biological markers that predict response. Participants recei…

This study tests different levels of a telephone-based weight loss program for cancer survivors who are overweight or obese. All participants start with a core program including written materials, a smartphone app, and optional coaching. Those who lose at least 2% of their weight…

This phase II trial is testing the drug trametinib in 50 people with advanced cancers that have a specific genetic change called an NF1 mutation. Trametinib blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from get…

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This early-phase trial is testing an experimental drug called SHR-A2009 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goals are to find a safe dose and to understand the drug's side effects and how t…

This study tests the safety of specially prepared T cells that target a protein called mesothelin, found on some breast cancer cells. The cells are collected from the patient's blood, modified in a lab, and then given back along with chemotherapy and another drug. The trial enrol…

This Phase I trial tests the safety and best dose of combining vorinostat with one of three mTOR inhibitors (sirolimus, everolimus, or temsirolimus) in up to 249 patients with advanced cancer that has not responded to standard treatments. The drugs aim to block cancer cell growth…

This study tests whether analyzing the genetic makeup of a patient's triple-negative breast cancer tumor can help doctors choose the most effective treatment. Patients with newly diagnosed, early-stage triple-negative breast cancer receive either standard chemotherapy or a person…

This study tested the drug pembrolizumab in 71 people with advanced inflammatory or triple-negative breast cancer that had spread or returned. Participants had already responded to chemotherapy. The goal was to see if pembrolizumab could keep the cancer from growing for at least …

This study tests a combination of two drugs—sacituzumab govitecan and talazoparib—in people with metastatic triple-negative breast cancer that has spread. The goal is to see if the combo can shrink tumors or slow the disease. About 75 adults with advanced cancer are taking part. …

This study tests whether the drug olaparib can help prevent breast cancer from returning in people with inherited BRCA1 or BRCA2 mutations who have already completed surgery and chemotherapy. About 1,800 participants with high-risk, HER2-negative breast cancer will receive either…

This study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…

This study tests a three-part approach for people with breast cancer that has spread to the brain. First, they receive focused radiation (stereotactic radiosurgery) along with a drug called olaparib, which may make cancer cells more sensitive to radiation. After that, they get an…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This study offers continued treatment with the cancer drug osimertinib to patients who have already benefited from it in a previous trial. The goal is to keep providing the drug while monitoring safety and side effects. About 37 adults with cancer who are still doing well on the …

This phase II trial is testing the drug palbociclib in 40 patients whose advanced cancers have extra copies of the CCND1, 2, or 3 genes. Palbociclib blocks proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. The study …

This early-phase trial tests an experimental drug called COH29 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. COH29 works by blocking an enzyme that cancer cells need to grow and multiply. The main g…

This pilot study tests whether a resistance training program using weighted sled pushes and pulls can help cancer patients improve muscle mass and reduce body fat. Thirty adults aged 20-89 with a cancer diagnosis will participate in monitored exercise sessions over six months. Re…

This study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…

This study tests a new drug called WJ47156, alone or combined with other anti-cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see early signs of tumor shrink…

This study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…

This study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…

This study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…

This study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can help the immune system attack HER2-negative breast cancer more effectively. About 46 adults with locally advanced disease will receive a short course of these d…

This phase 2 trial tests whether a vaccine made from a protein found on many triple-negative breast cancer cells can help prevent the cancer from coming back. Participants receive the vaccine along with an immune booster and a low dose of chemotherapy. The study includes women wi…

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This study tests whether taking enzalutamide for one year after standard treatment is practical for people with early-stage triple negative breast cancer that has androgen receptors. About 50 participants will take the drug and report on their quality of life. The main goal is to…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This early-phase study tests whether adding the drug niraparib to standard radiation therapy after surgery can help prevent triple negative breast cancer from coming back. Niraparib is a PARP inhibitor that blocks cancer cells from repairing their DNA. The study includes 21 adult…

This study tests whether combining two drugs (niraparib and dostarlimab) with radiation therapy is safe and effective for people with metastatic triple-negative breast cancer that has not responded to immunotherapy or is PD-L1 negative. About 32 adults with this aggressive cancer…

This early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This early-stage study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with advanced or recurrent solid tumors that have specific genetic changes. The main goal is to find the safest dose with the fewest side effects. The…

This early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…

This study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…

This early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …

This phase III trial tests whether personalized therapy can improve survival for people with high-risk BRCA1-like breast cancer. Participants receive either standard chemotherapy or a more intense regimen with stem cell rescue. The study aims to find a better way to treat this ag…

This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…

This study tests two drugs, niraparib and dostarlimab, given before surgery to people with BRCA- or PALB2-mutated breast cancer. The goal is to see if this combination boosts the immune system's attack on the tumor and leads to a complete response (no cancer left at surgery). Abo…

This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can completely eliminate tumors in people with localized triple-negative breast cancer. About 51 women with early-stage, untreated disease will receive the combination, then…

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,100 participants will take part in this early-phase trial.

This study tests whether adding the drug ipatasertib to standard chemotherapy and immunotherapy (atezolizumab) can improve outcomes for women with high-risk triple-negative breast cancer before surgery. About 146 women with newly diagnosed, non-metastatic tumors that are at least…

This study looks at whether women with aggressive breast cancers (triple-negative or HER2-positive) who have a complete response to chemotherapy can safely avoid sentinel lymph node biopsy. The trial will enroll 350 patients across Europe, all of whom will have breast-conserving …

This early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…

This phase 3 trial tests whether adding the drug carboplatin to standard chemotherapy (doxorubicin, cyclophosphamide, and paclitaxel) helps prevent triple-negative breast cancer from coming back. About 782 patients with high-risk or node-positive disease are participating. The st…

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This study tests a new drug called PF-07104091 in people with advanced small cell lung cancer, ovarian cancer, or certain breast cancers that have not responded to prior treatments. The goal is to find the safest dose and see if the drug shrinks tumors, either alone or with other…

This was a phase II trial testing a combination of three drugs—zimberelimab, domvanalimab, and sacituzumab govitecan—as a first treatment for people with advanced triple-negative breast cancer that is PD-L1 positive. The study aimed to see how well the drugs shrank tumors and how…

This study aimed to test an experimental treatment called GT316, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological cancers. The goal was to check the safety and side effects of this cell therapy. However, the study was withdrawn b…

This early-phase trial tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 people with advanced solid tumors that have stopped responding to other treatments. The drug is wrapped in a special polymer to make it smaller, which may help it reach deeper into …

This phase 2 trial tests whether the number of immune cells in and around a triple-negative breast cancer tumor can help doctors personalize chemotherapy and immunotherapy. About 139 women with early-stage triple-negative breast cancer will receive standard chemotherapy drugs plu…

This phase II trial aimed to test the drug itacitinib in people with severe side effects from cancer immunotherapy that did not get better with steroids. The goal was to see if itacitinib could calm the overactive immune response causing these side effects. However, the study was…

This study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy is safe and works for people with metastatic triple negative breast cancer, a hard-to-treat form. 29 adults with advanced cancer that had spread or could not be removed by surgery took …

This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to the chemotherapy pill capecitabine helps prevent cancer from coming back in people with triple-negative breast cancer who still had cancer after initial chemotherapy and surgery. About 284 participants…

This Phase 3 trial tests whether the drug sacituzumab govitecan (Trodelvy) can prevent breast cancer from returning in patients with HER2-negative breast cancer who still have cancer after initial chemotherapy. About 1,332 participants will receive either the new drug or standard…

This study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the combination can shrink tumors. About 216 adults aged 18 to 75 with good perfor…

This study tests a technique called axillary reverse mapping (ARM) to see if it can prevent lymphedema—painful arm swelling—after breast cancer surgery. About 534 people with stage I-III breast cancer will be followed for 3 years. The goal is to find out if mapping and preserving…

This Phase 2 trial is testing a drug called PRL3-zumab in 60 people with advanced solid tumors that have not responded to standard treatments. PRL3-zumab is an antibody designed to attach to a protein called PRL3 found on cancer cells, potentially helping the immune system attack…

This early-phase trial is testing two different doses of vorinostat (a drug that blocks enzymes needed for cancer cell growth) combined with either carboplatin or paclitaxel (standard chemotherapy drugs) in 20 people with advanced solid tumors that have not responded to other tre…

This study tests whether giving the immunotherapy drug pembrolizumab (Keytruda) along with a small dose of radiation to the tumor before standard treatment (surgery, chemotherapy, or radiation) is safe and helps the immune system fight breast cancer. About 66 people with operable…

This phase 2 trial tests whether combining immunotherapy (avelumab) with other drugs can shrink tumors in people with advanced triple-negative breast cancer that has spread or come back. About 145 participants will receive one of several drug combinations, including avelumab plus…

This early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled,…

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…

This early-phase trial tests a personalized immunotherapy called MVX-ONCO-2 for people with advanced solid tumors that have not responded to standard treatments. The vaccine is made from the patient's own tumor cells and aims to boost the immune system to fight the cancer. The st…

This study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…

This study tests a combination of three drugs (nivolumab, bicalutamide, and ipilimumab) in 30 people with advanced HER2-negative breast cancer that has spread. The goal is to see if this chemo-free approach can control the disease for at least 24 weeks. Participants must have mea…

This phase 3 study compares a targeted drug called sacituzumab govitecan against standard chemotherapy in about 623 people with advanced triple-negative breast cancer that does not express PD-L1 (a protein that makes immunotherapy work). Participants either have not received prio…

This phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This phase II trial is testing whether giving two chemotherapy drugs, carboplatin and nab-paclitaxel, before surgery can improve outcomes for people with locally advanced or inflammatory triple negative breast cancer. The goal is to see if this approach increases the rate of comp…

This study tests two immunotherapy drugs, durvalumab and tremelimumab, alone or together with standard chemotherapy in people with advanced solid tumors that cannot be cured. The main goal is to find the highest safe dose that does not cause severe side effects. About 153 partici…

This study looks at whether women with triple-negative or HER2-positive breast cancer who have a complete response to chemotherapy can safely skip sentinel lymph node biopsy. The trial will compare standard surgery plus biopsy versus surgery alone, measuring how often cancer retu…

This phase II trial is testing whether a pre-treatment biopsy can predict how well patients with locally recurrent or metastatic triple negative breast cancer respond to cisplatin chemotherapy combined with radiation therapy. About 49 participants will receive the treatment, and …

This early-phase study tests a new drug called 3D185 in 42 adults with advanced solid tumors who have run out of standard treatments. The main goals are to check the drug's safety and how the body processes it, while also looking for any signs that it might shrink tumors. This is…

This study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors or co…

This early-phase trial tests a new type of immune cell therapy called NW-301VT for people with advanced solid tumors that have a specific KRAS mutation (G12V) and no standard treatment options. The therapy uses the patient's own T cells, which are genetically engineered to recogn…

This study tests whether adding two experimental drugs (AK117 and AK112) to standard chemotherapy can shrink tumors in people with advanced triple-negative breast cancer that hasn't been treated yet. About 120 participants will receive the combination. The main goals are to see h…

This phase 2 study tests a combination of camrelizumab (an immunotherapy), risedronate (a bone drug), and chemotherapy in 30 women with triple-negative breast cancer. The goal is to see if adding risedronate can help overcome resistance to standard treatment and improve tumor shr…

This study tests a new drug (MEN1611) combined with chemotherapy (eribulin) for people with advanced breast cancer that has specific genetic changes (PIK3CA/PTEN). The goal is to see if the combination can shrink tumors or stop them from growing. About 14 participants will receiv…

This early-phase trial tests whether adding a single, focused dose of radiation before surgery can make the immunotherapy drug pembrolizumab work better in people with early-stage breast cancer. About 27 participants will receive both treatments, then have surgery to see if the t…

This early-phase study tests a new drug called HRS-6209 in about 56 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This study is testing a new combination of two drugs (AK112 and AK117) in about 154 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and how safe it is. Participants receive the drugs intrave…

This early-phase trial tests IBI363, a drug designed to both stimulate immune cells and block a cancer defense, in about 40 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goal is to find a safe dose and check for side effec…

This study tests a new drug called brenetafusp for adults with advanced solid tumors that have a specific marker (PRAME) and tissue type (HLA-A*02:01). The drug is designed to help the immune system find and attack cancer cells. The goal is to check if it is safe and if it can sh…

This early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.

This study tests an oral drug called TAK-788 (mobocertinib) in adults with advanced non-small cell lung cancer. The goal is to find the best dose, check safety, and see if the drug shrinks tumors. Participants take TAK-788 capsules, sometimes with chemotherapy, and continue treat…

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

This trial is testing whether giving a small dose of targeted radiation to a part of the breast tumor before standard chemotherapy can help the immune system fight the cancer more effectively. The study includes 40 people with high-risk or locally advanced breast cancer. After ra…

This study was designed to test whether adding the experimental drug boserolimab to standard chemotherapy and immunotherapy before surgery could help people with high-risk, early-stage triple-negative breast cancer. The goal was to see if the combination was safe and could elimin…

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…

This study aimed to see if the drug trastuzumab deruxtecan worked better than standard CDK4/6 inhibitors for people with a specific advanced breast cancer (ER-positive, HER2-low, non-luminal A). It was designed for adults with metastatic disease. However, the trial was withdrawn …

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This study tests a combination of two immunotherapy drugs (tiragolumab and atezolizumab) plus chemotherapy in 81 women with triple negative breast cancer. It includes two groups: those with early-stage cancer and those with advanced (metastatic) cancer. The goal is to see if the …

This early-stage trial tests a new drug called SON-1010 in 42 adults with advanced solid tumors that have spread or cannot be removed. The drug is designed to hitch a ride on a blood protein called albumin to deliver an immune-boosting signal (IL-12) directly to the tumor area. T…

This study tests a drug called sacituzumab govitecan in 80 Chinese patients with metastatic triple-negative breast cancer who have already tried at least two other treatments. The goal is to see if the drug can shrink tumors or slow the disease. Participants receive the drug intr…

This study tests whether giving stereotactic body radiotherapy (SBRT) to growing metastatic tumors can delay overall cancer progression. About 107 adults with triple-negative breast cancer or non-small cell lung cancer that has started to grow in a few spots will receive SBRT or …

This study tests a new drug called HCB101 given together with other cancer treatments for people with advanced solid tumors that have not responded well to prior therapy. About 500 adults will take part to find the safest dose and see if the combination can shrink tumors. The goa…

This study tests a new drug called HB0025 combined with chemotherapy (nab-paclitaxel) as a first treatment for people with advanced triple-negative breast cancer that cannot be removed by surgery. The goal is to see if the combination is safe and works better than chemotherapy al…

This phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…

This early-stage study tests an experimental drug called FDA018-ADC in about 78 adults with advanced solid tumors (like breast, lung, or bladder cancer) who have run out of standard options. The main goals are to find a safe dose and check for side effects, while also seeing if t…

This early-stage trial tests the safety and tolerability of a new drug called SH006 in 50 adults with advanced solid tumors, including liver cancer. Participants receive SH006 every three weeks. The study aims to find the best dose for future trials and monitor side effects. It i…

This phase 3 trial tests a new drug called FDA018-ADC against standard chemotherapy in 350 people with advanced triple-negative breast cancer that has worsened after taxane treatment. The study compares how long the cancer stays under control and overall survival. Participants ar…

This study tests a combination of two drugs, sacituzumab govitecan and bevacizumab, in people with metastatic triple-negative breast cancer that has progressed after at least one prior treatment. The trial will enroll 60 participants across several centers in China. Researchers w…

This early-stage study tests a new treatment called ACIT-1, which uses donated immune cells to help fight cancer. About 34 adults with pancreatic or other cancers will receive one of four doses to find the safest and most effective dose. The goal is to see if the therapy can safe…

This study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will ta…

This study tests a new drug called BT7480, given alone or with another drug (nivolumab), in 200 people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug shrinks tumors. It is an early-stage t…

This early-stage study tests a new drug, TORL-2-307-ADC, in 163 people with advanced solid tumors like stomach, pancreas, or esophageal cancer. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have measurable disease and be well enough for …

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…

This study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…

This phase 2 trial is testing a drug called taletrectinib in 217 people with advanced or metastatic ROS1-positive non-small cell lung cancer and other solid tumors. The main goal is to see how well the drug shrinks tumors and to check its safety. Participants take the drug by mou…

This phase 3 trial tests whether adding capivasertib (a targeted drug) to standard chemotherapy (paclitaxel) helps people with advanced triple-negative breast cancer live longer. About 923 participants receive either the combination or a placebo plus chemotherapy. The study is no…

This study tests a new combination of two drugs (Debio 0123 and sacituzumab govitecan) in people with advanced breast cancer that has not responded to prior treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 76 adults with triple-n…

This early-phase study tests a new drug called GH2616 in about 126 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a protein (KIF18A) that helps cancer cells divide, which may slow or stop tumor growth. The main goals are …

This phase 3 trial tests whether combining sacituzumab govitecan (Trodelvy) with pembrolizumab (Keytruda) works better than standard chemotherapy plus pembrolizumab for people with advanced triple-negative breast cancer that has a protein called PD-L1. About 443 participants who …

This study was designed to test a combination of two drugs, Ezabenlimab and BI907828, in people with advanced solid tumors like sarcoma, lung cancer, and breast cancer. The goal was to see if the treatment could control the disease for at least 24 weeks. However, the trial was wi…

This study is testing whether regular MRI scans of the brain can find cancer that has spread from the breast to the brain, even before symptoms appear. It involves 214 people with metastatic or inflammatory breast cancer. The goal is to see if early detection through screening im…

This expanded access program lets people with advanced solid tumors receive an investigational imaging agent called MNPR-101-DFO*-89Zr before a PET/CT scan. The agent is designed to bind to uPAR, a protein found at higher levels in some tumors than in normal tissue. The goal is t…

Researchers are testing an experimental imaging agent called MNPR-101-DFO*-89Zr in people with several types of solid tumors, including bladder, breast, lung, and pancreatic cancers. The agent combines an antibody with a radioactive label, which may help PET scans reveal where tu…

This early-stage trial is testing whether a new radioactive imaging agent, called [99mTc]Tc-DARPinEc1-G3C, can safely and effectively visualize breast cancer tumors using SPECT/CT imaging. The study involves about 10 people with primary triple-negative or luminal breast cancer. P…

This trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…

This phase I trial tests an experimental imaging agent called 64Cu-DOTA-pembrolizumab, which is designed to attach to PD1, a protein on immune cells that often cluster around tumors. By injecting this agent and then performing a PET scan, researchers hope to see where these immun…

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…

This trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…

This trial is testing an experimental imaging agent called [68Ga]Ga-ELI411, which is designed to bind to a protein (FAP) found in many solid tumors. The study will involve 18 adults with confirmed solid tumors who are already scheduled for a standard FDG-PET scan. Participants wi…

This study tests a new device that measures blood counts from a tiny finger-prick sample in cancer patients. Researchers will compare these results to standard lab tests from regular blood draws. The goal is to see if the device is accurate enough to eventually allow patients to …

This study explores whether special ultrasound techniques can detect early signs that cancer immunotherapy is working. Researchers will scan tumors in 30 adults with solid tumors before and after three weeks of treatment. The goal is to see if changes in blood flow measured by ul…

This study aims to create a screening tool that uses common blood test results to detect various cancers early. Researchers will analyze data from 10 million cancer patients and healthy individuals, using machine learning to find patterns. The goal is a low-cost, non-invasive tes…

This pilot study tests a new type of breast scan called DBT-TOBI, which combines 3D mammography with light-based imaging. Researchers want to see if it can predict how well breast cancer responds to chemotherapy early in treatment. The study involves 30 women with HER2+ or triple…

This study tests whether a simple 30-second ECG using a handheld device can find undiagnosed atrial fibrillation (an irregular heartbeat) in people aged 65 and older with cancer. About 500 participants will be randomly assigned to either get the quick screening or usual care. The…

This study looks at whether liquid biopsies—simple blood tests that detect tumor DNA—can be used during regular doctor visits for people with advanced solid tumors. Researchers will collect blood samples from 159 patients and measure ctDNA levels to see how often the test finds t…

This pilot study aimed to test whether a radioactive imaging agent called 68Ga-FAPI-46 could predict how well solid tumor patients respond to antibody therapy. The plan was to give 50 participants an injection of the agent, then perform a PET/CT scan and compare it to standard MR…

This study tests whether empagliflozin, a drug used for diabetes, can prevent heart damage in cancer patients receiving strong chemotherapy (anthracyclines). About 220 adults with cancer but no prior heart failure will take either the drug or a placebo daily for 12 months. The go…

This study tests whether taking an over-the-counter probiotic (VSL#3® 450B) can prevent colitis (colon inflammation) and diarrhea in cancer patients receiving immunotherapy. Up to 45% of patients on these drugs develop this side effect. The trial enrolls adults with solid tumors …

This study tests a type of talk therapy called dignity therapy, adapted for sexual and gender minority (LGBTQ+) cancer patients. A trained researcher will interview participants about their lives and create a poem or legacy document they can share with loved ones. The goal is to …

Depression is common among cancer survivors, but many don't get help. This pilot study tests a text-based referral platform that sends tailored messages and a video to encourage survivors to take up a mental health referral. The study will enroll 60 cancer survivors with depressi…

This study tests a program called CostCOM that helps cancer patients with the high costs of treatment. Many patients skip or delay care because of money worries. The program provides financial advice and connects patients to resources. Researchers want to see if it helps patients…

This pilot study explores how four different meditation practices—breathing only, focused attention only, mindfulness only, and a combination of all three—affect relaxation in cancer survivors. Many cancer patients experience stress and anxiety, and meditation may help reduce dis…

This study tests a program called ASCENT that helps cancer survivors manage pain using an educational guide and coaching from community health workers and pain care managers. The goal is to improve pain control and lower the risk of opioid misuse. About 660 adults with cancer-rel…

This study tests whether inhaling lavender aromatherapy oil can reduce anxiety and pain for cancer patients undergoing a bone marrow biopsy. About 45 adults with cancer will be asked to use the oil during the procedure. The goal is to see if this simple, drug-free approach is som…

This study tests a communication coaching program for adolescent and young adult cancer survivors (ages 18-35) who have finished treatment at least a year ago. Participants complete online sessions and AI coaching to improve how they talk with peers. The goal is to see if the pro…

This trial tests whether six weeks of upper cervical chiropractic care can help adults who have finished cancer treatment but still struggle with chronic fatigue. The study focuses on whether such a trial is practical, looking at recruitment, adherence, and acceptability. Partici…

This study tests a program called TIPPI-R that teaches children with cancer and their families ways to manage pain and distress during treatment. About 100 children aged 0-18 will either receive the program or standard care. Researchers will compare how well they cope with pain a…

This study tests whether group education sessions can help veterans with newly diagnosed cancer discuss their goals of care and complete advance directives. Fifty veterans will attend two virtual or in-person sessions led by a trained health educator. Researchers will check if th…

This pilot trial tests whether Acceptance and Commitment Therapy (ACT), a type of talking therapy, can help disease-free cancer survivors manage chronic pain and reduce long-term opioid use. Participants attend six weekly virtual sessions with a psychologist. The study focuses on…

This study tests whether an internet-based pain coping skills program can help cancer survivors manage ongoing pain. About 456 adults who have completed cancer treatment or are on maintenance therapy will take part. Participants will either get the online program plus enhanced us…

This study tests if fast-acting opioids (fentanyl or morphine) can reduce shortness of breath during or after walking in 150 cancer patients who already take strong painkillers. Participants will take the drug or a placebo before a short walk test, and researchers will measure ch…

This study tests whether an open labeled placebo—a pill with no active medicine that patients know is a placebo—can reduce fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply takin…

This trial tests whether a virtual reality (VR) educational video can reduce anxiety and improve satisfaction in adults starting their first course of external beam radiotherapy for cancer. Half of the 122 participants will watch a VR video through a headset before treatment, whi…

This study tests an online pathway called iPath*D that guides cancer patients who report depression symptoms from screening to treatment options. The goal is to see if the tool is acceptable and easy to use for adults starting cancer treatment. Researchers will measure usability,…

This study tests a digital program called EMBody for cancer survivors aged 16-25 who finished treatment up to seven years ago. The program uses short films and reflection activities to help them develop a healthier mindset about their body. Researchers want to see if it improves …

This study tests whether rituximab or tocilizumab can help people with advanced cancer stop taking steroids for side effects caused by immunotherapy. About 8 participants will receive one of these drugs to see if they can safely reduce or stop steroid treatment within 4 weeks. Th…

This study tests whether adding a trained community health worker (CHW) to standard care can improve quality of life and advance care planning for African American patients with advanced cancer. 160 patients will either receive standard care or standard care plus CHW support. The…

This trial tests a mindfulness program that blends stress-reduction techniques with Christian principles to improve well-being in Black adult cancer survivors. Participants take part in a silent mindfulness retreat, focus groups, interviews, and questionnaires. The study measures…

This study tests whether a smartphone app that teaches mindfulness can help reduce stress in people who have finished cancer treatment. About 345 cancer survivors will be randomly assigned to use the app right away or wait three months. The goal is to see if the app makes a real …

This study looks at whether adding lorazepam to haloperidol can better reduce delirium (sudden confusion and agitation) in people with advanced cancer who are in a palliative care unit. About 93 participants will receive either haloperidol alone or with lorazepam, and their level…

This study tests whether a virtual group writing program can improve quality of life for young adults who survived cancer. Thirty survivors aged 18-39, diagnosed 1-5 years ago, will write about their cancer experiences in a group setting. The goal is to see if this simple, access…

This study tests whether using virtual reality (VR) can improve symptoms like pain, anxiety, and fatigue in patients receiving a bone marrow transplant. About 28 adults will be randomly assigned to either VR sessions or standard care during their hospital stay. The goal is to see…

This study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…

This study explores whether a structured survivorship care visit, conducted early in cancer treatment, can help reduce psychological distress and improve quality of life. Adults with any type of cancer who report significant distress will meet with a physician assistant to discus…

This phase 2 trial tests whether a daily dose of EGCG, a compound found in green tea, can reduce frailty and inflammation in people aged 65 and older who have survived cancer. About 118 participants will take either EGCG or a placebo for 12 weeks. The study is currently suspended…

This study tests whether a financial navigation and counseling program (CostCOM) can help newly diagnosed cancer patients who are struggling with costs or basic needs like food and housing. About 91 patients will either get the program, educational materials, or usual care. The g…

This study tests whether an over-the-counter herbal pain patch, called Tibetree Pain Relieving Plaster, can reduce muscle and joint pain in people who have finished active cancer treatment. Sixty-eight cancer survivors will apply either the active patch or a placebo patch to thei…

This study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…

This study tests whether a phone app can help people with chest-area cancers and their caregivers report symptoms early and request palliative care on their own. The goal is to improve quality of life by managing pain and stress sooner. About 157 participants will use the app to …

This study tests a 7-session, peer-led self-management program for 234 cancer survivors who recently finished treatment with curative intent. The program aims to reduce anxiety and depression by teaching symptom management skills in a group setting. Participants are from central …

This study is testing a 5-session telehealth program called CASA that helps advanced cancer patients and their caregivers cope with emotional and spiritual challenges. The program is designed for people with stage III or IV cancer and their caregivers. The goal is to see if it im…

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This study tests a 9-week virtual program that helps cancer survivors build social connections and reduce loneliness. Participants work one-on-one with a facilitator to create a personalized action plan. The goal is to see if this approach improves well-being and quality of life.

This study compares a 12-week digital home-based resistance exercise program to a supervised on-site program for cancer survivors who finished treatment up to 5 years ago. The main goal is to see which approach leads to better exercise adherence. Researchers will also measure eff…

This study compares listening to Holy Qur'an recitation versus calming music before bed in children aged 6 to 10 who are undergoing chemotherapy. Sleep problems are common in these children, and the goal is to find a safe, non-medication way to improve sleep quality. Ninety child…

This study tests whether a special type of counseling called hope-focused motivational interviewing can improve hope, self-confidence, and self-compassion in cancer patients who are getting radiation therapy. About 46 adults with early-stage cancer will be randomly assigned to re…

This study aims to find the best way to deliver cognitive behavioral therapy for insomnia (CBT-I) to cancer survivors who have chronic sleep problems. Researchers are comparing individual vs. group sessions and whether adding booster sessions helps. The goal is to create an effec…

This study tests whether up to two doses of psilocybin (the active ingredient in magic mushrooms) can safely reduce depression in adults who have both cancer and major depressive disorder. About 56 participants will receive either psilocybin or a placebo in a first session, and t…

This study looks at whether personalized exercise plans delivered through a Fitbit and a smartphone app can help cancer survivors become more physically active. Researchers will track steps, weight, quality of life, and emotional well-being in 160 adult survivors who have finishe…

This study tests a pre-surgical toolkit (OPTI-Surg) designed to help older cancer patients recover more quickly after major surgery. The toolkit provides recommendations before surgery to improve physical function and reduce complications. About 325 participants with various canc…

This study looks at whether an 8-week digital program called COBRA, which includes balance and resistance exercises, is safe and practical for older adults with cancer. The program is delivered via an iPad with video calls. Researchers will track how many participants stick with …

This study tests whether a brief behavioral therapy (BBT-CI) or a healthy eating education program (HEAL) works better for reducing insomnia in cancer patients. About 400 adults with stage I-IV cancer who are currently receiving treatment and have sleep problems will take part. T…

This study tests whether a structured exercise program can reduce chemotherapy-induced peripheral neuropathy (CIPN) — nerve damage causing pain, numbness, or tingling. About 133 cancer patients who received certain chemotherapies will either follow an exercise plan or receive sta…

This study looks at whether using activity trackers and a phone app can help people with cancer reach their exercise goals during treatment. Twenty-five participants will wear the trackers for three months. The goal is to see if this approach is practical and helpful for both pat…

This study tests whether virtual yoga classes can help cancer survivors who have trouble sleeping. About 42 survivors will either take 8 virtual yoga sessions over 4 weeks or continue their usual care. Researchers will measure changes in insomnia and sleep quality to see if the o…

This study tests a group program called the Relaxation Response Resiliency Program (3RP-AYA) for adolescents and young adults who finished cancer treatment in the last 5 years. The program uses mind-body techniques like imagery, relaxation, and yoga to reduce stress and build res…

This study tests whether a mobile app called SUPPORT+ can improve quality of life for adults with advanced cancer who are no longer receiving anticancer treatment. Participants use the app to report symptoms weekly, get self-care tips, and receive nurse follow-up if symptoms are …

This pilot study explores whether chiropractic adjustments to the upper neck can reduce chronic fatigue in adults who have finished cancer treatment. About 40 cancer survivors who are currently cancer-free will receive either immediate or delayed chiropractic care for 6 to 12 wee…

This study gives 250 advanced cancer patients $1,000 each month for a year to see if it reduces financial stress and improves quality of life. Participants also complete surveys every three months. The goal is to learn whether extra income can help patients stick to treatments an…

This study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…

This study tests an electronic symptom management system called Nurse AMIE in 344 people with stage 3 or 4 cancer living in rural areas. The goal is to see if using the system helps them live longer and improves their quality of life. Participants use the system to report symptom…

This study aimed to see if a special needle treatment (ultrasound-guided neuromodulation) could reduce front knee pain in cancer patients better than standard painkillers. It was planned for adults aged 18-65 with knee pain related to cancer. However, the study was withdrawn befo…

This trial was designed to see if nerve stimulation techniques could reduce lower limb pain in cancer patients better than medication. It was withdrawn before enrolling any participants, so no results are available. The study would have compared ultrasound-guided percutaneous neu…

This study compares two brief online educational programs for young women (ages 19-49) who have finished cancer treatment and are dealing with sexual health issues. Participants join video sessions and report changes in sexual function and emotional well-being. The goal is to fin…

This study tests whether cancer patients who visit the emergency room for urgent problems benefit from being immediately referred to a palliative care team. The goal is to see if this reduces aggressive treatments and hospitalizations in the last month of life. The trial involves…

This study looks at whether a supervised exercise program in community settings can improve quality of life and reduce fatigue in adults with cancer. 492 participants, including survivors and those on active treatment, will take part in group exercise sessions. Researchers will t…

This study tests whether electroacupuncture (a type of acupuncture with mild electrical pulses) can help cancer patients and survivors with clusters of symptoms like memory problems, fatigue, insomnia, anxiety, and depression. Seventy participants will receive either real electro…

This study tests whether a mobile health program can help adolescents and young adults (ages 15-39) who finished cancer treatment become more physically active. Participants get a personalized activity plan, a fitness tracker, access to an online survivor community, and motivatio…

This study tests whether a phone app called OnKO-Tips&Tricks can improve the quality of life for adolescents and young adults (ages 15-25) recently diagnosed with cancer. The app helps with daily check-ins, education, and connecting with a nurse coordinator. Researchers will comp…

This study tests whether nature-based therapies can reduce fatigue and improve sleep, mood, and concentration in cancer survivors. 172 participants will be assigned to real forest bathing, a virtual reality forest experience, guided imagery, or a waitlist. Each session lasts 30 m…

This study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…

This study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…

This study is testing a 24-week program that combines nutrition counseling, exercise, sleep tips, and stress management for cancer survivors who are overweight. Researchers want to see if the program is practical and helpful for improving sleep quality, reducing stress, and boost…

This study enrolls up to 10,000 cancer patients at the National Cancer Institute who are not on an active treatment research protocol. Participants receive standard medical care, including lab tests and scans, while researchers collect their health information to build a data rep…

This study will collect blood and tumor tissue from up to 50,000 adults with hereditary or genetic-linked cancers. Researchers will use these samples to create lab-grown tumor models, like mini-tumors, to study how these cancers work and test new treatments. The goal is to better…

Researchers are testing an online decision support tool called Gene PilotLX to see if it helps Latinx cancer patients make informed choices about tumor genomic testing. Tumor genomic testing looks for genetic changes in a tumor that might guide treatment or reveal hereditary risk…

This study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects caused by the drug. By understanding these risks, doctors hope to prevent or reduce them in future cancer treatments.

This study looks back at the medical records of 500 children and adults with cancer who received immunotherapy at the National Cancer Institute. The goal is to understand the side effects, like inflammation and immune reactions, that can happen with these treatments. By learning …

This study aims to map the genetic makeup of breast and prostate cancers in patients treated through Brazil's public health system. Researchers will analyze tumor and normal DNA from 882 participants to build a national database. The goal is to better understand how genetics and …

This study tests whether an AI tool can accurately summarize serious illness conversations between doctors and cancer patients. Researchers will send these summaries to doctors caring for hospitalized patients with advanced cancer. The goal is to see if the summaries are accurate…

This study looks at whether watching an online genetics video, with or without phone counseling from a genetic counselor, can reduce the stress women feel about their cancer risk. It involves 5,200 women aged 30 or older who have had triple-negative breast cancer and still have a…

This study looks at how children with cancer and their parents handle the emotional challenges of the disease. Instead of focusing only on negative effects like posttraumatic stress, researchers also explore positive changes, such as personal growth. The study compares these fami…

This study surveys over 1,200 cancer patients who previously took part in behavioral trials to learn how the COVID-19 pandemic impacted their quality of life, mental health, and daily routines. Participants fill out questionnaires about stress, sleep, diet, exercise, and social s…

This study explores whether a special MRI scan can serve as a non-invasive biomarker to predict how early breast cancer responds to immunotherapy. Researchers will compare MRI features with tissue and blood samples from about 10 patients with hormone receptor-negative, HER2-negat…

This study tests a digital platform called ConnectedNest that helps cancer patients find and connect with social services like housing assistance, food aid, and financial help. About 400 adults with cancer in Minnesota will use the platform for 90 days. Researchers will measure i…

This study enrolls 50 adults with any type of cancer to test whether watching a video and reading a handout improves their knowledge and beliefs about cancer clinical trials. Participants complete a survey before and after the educational materials to measure any change. The goal…

This study aims to understand the experiences of cancer patients who receive care at home through MD Anderson's Care and Monitoring at Home program. Researchers will use surveys to measure quality of life and gather feedback from up to 40 participants. The goal is to learn whethe…

This trial tests whether a structured, nurse-led symptom screening program can increase the number of cancer survivors who are screened for distress and referred to supportive services. The program includes nurse training and regular feedback, and it will be rolled out across mul…

This study looks at whether a new scoring system, called the DIEP-MDS, can help predict the risk of blood flow problems and flap failure after DIEP flap breast reconstruction. The score is based on CT scans of the abdomen, measuring features of the blood vessels used in the surge…

This study tests whether a simple questionnaire, filled out by children and teens with cancer (and their caregivers) before and after a clinic visit, can help doctors better understand their symptoms. About 85 participants will use the tool during routine visits. The goal is to s…

This study aims to find out how often cancer patients treated with opioids for pain are at risk of misusing these medications. Researchers will use two screening questionnaires to assess misuse risk in 200 adult outpatients receiving opioids for cancer-related pain. The findings …

This study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study looks at how often cancer patients experience cachexia (unintentional weight loss and appetite loss) and how this affects both patients and their primary caregivers emotionally. About 192 patients and their caregivers will fill out questionnaires during supportive care…

This study is for women with breast cancer who are receiving a treatment that greatly lowers estrogen levels. Researchers want to see if this treatment changes how the heart works. They will use heart scans to measure blood flow in 90 women over two years. The goal is to learn mo…

This study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…

This study looks at how cancer patients use complementary and alternative medicine (CAM), such as herbal products and aromatherapy. Researchers will survey 500 patients and hold focus groups with 30-60 survivors to understand their needs, information sources, and any potential sa…

This study is looking at how triple-negative breast cancer evolves during chemotherapy. Researchers will take biopsies from the tumor before, during, and after treatment to see if the diversity of cancer cells affects how well the tumor responds. The goal is to understand why som…

This study is testing whether a chatbot can help parents of children with cancer learn about genetic risks and decide whether to get tested themselves. The chatbot provides education and support as an alternative to speaking with a genetic counselor. The goal is to make it easier…

This study is testing whether a new device called Liberty can accurately measure blood counts from a finger-prick sample compared to standard venous blood draws. Researchers will collect paired capillary and venous blood samples from healthy volunteers and cancer patients receivi…

This large observational study looks at whether getting an mRNA COVID-19 vaccine shortly before or after starting immune checkpoint inhibitor therapy is linked to longer survival in adults with cancer. Using data from nearly 100,000 patients in France, researchers are comparing t…

This study looks at whether a broad genetic test (microarray PGx) can find more drug-gene interactions than the standard single-gene test in 120 adults with cancer who are about to receive chemotherapy. The goal is to see if this extra information could help doctors adjust drug d…

This study looks at how community cancer clinics screen for health-related social needs, like help with housing, food, or transportation. Researchers will work with 144 clinic staff to understand what helps or hinders screening. The goal is to create custom plans to make screenin…

This study at St. Jude Children's Research Hospital is testing whether a next-generation DNA test can predict bloodstream infections in children and teens with cancer who are at high risk. Current methods often detect infections too late, leading to severe illness or death. The g…

This study compares two different information sheets given to advanced cancer patients and their caregivers before a doctor visit. One sheet has sample questions to ask, the other has general information. The goal is to see which one helps patients and caregivers communicate bett…

This study explores whether genetic testing from a simple saliva sample can improve risk assessment for breast cancer in women who need a breast biopsy. Researchers will analyze DNA from saliva to calculate a polygenic risk score and compare it with biopsy results and medical rec…

This study looks at how the COVID-19 pandemic impacted the well-being and quality of life of over 13,000 cancer patients and survivors. Researchers used questionnaires to gather information on experiences like exposure, isolation, and financial disruptions. The goal is to underst…

This study is developing an artificial intelligence model that can analyze frozen-section pathology images—tissue samples examined during surgery. The goal is to help pathologists quickly and accurately diagnose cancer while the patient is still in the operating room. Researchers…

This study looks at tumor samples from over 3,000 people with advanced cancers to find specific biomarkers—unique features of each cancer. The goal is to help doctors choose the most promising targeted therapy or clinical trial for each patient. Participants are adults with vario…

This study follows 900 cancer survivors from six small island nations (Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia, and Saint Vincent) to understand how traveling overseas for cancer treatment affects their health and social support. Researchers will compare those who se…

This trial tests whether a pharmacist-led educational program helps cancer patients on high-risk chemotherapy better understand and follow neutropenic precautions—steps to prevent serious infections when white blood cell counts are low. About 300 adults with various cancers will …

This study creates a registry of cancer patients who have had their tumor genes analyzed. Participants fill out a 10-minute survey about their exercise habits before and after diagnosis. Researchers will look for connections between physical activity and genetic changes in tumors…

This study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…

This study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…

This study tests a special PET scan (FES) that tracks estrogen receptors in breast cancer tumors. Researchers want to see if changes in scan results before, during, and after hormone therapy can show how well the treatment is working. The study involves adults with estrogen recep…

This study tests a training program called CASCADE for family caregivers of people with advanced cancer. The goal is to see which parts of the training best help caregivers support patients in making medical decisions. 256 caregivers are taking part in different combinations of c…

This study tests whether giving cancer patients a drug vigilance card helps them avoid medication errors and interactions when seeing other doctors. One hundred patients on oral chemotherapy or targeted therapies at Limoges University Hospital will use the card. Researchers will …

This study tests whether a wearable patch called TempTraq can detect fevers earlier than standard temperature checks in cancer patients receiving immunotherapy. The goal is to see if continuous monitoring reduces the risk of severe cytokine release syndrome (CRS), a serious side …

This observational study tracks how doctors treat advanced triple-negative breast cancer in Canada, the UK, France, and Spain. Researchers will look at real-world data from 760 patients to understand treatment patterns and outcomes. No new drugs are being tested—the goal is to ga…

This study aims to create a comprehensive precision oncology platform at the Chinese University of Hong Kong to personalize drug therapy for 170 patients with advanced gastrointestinal cancers. Researchers will collect tumor samples for genetic sequencing and grow patient-derived…

This study looks at a program where cancer patients report their symptoms from home using a computer or phone. A navigator helps manage those symptoms. The goal is to see if this approach improves patient care and reduces emergency visits. About 3,090 adults with cancer are takin…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study tested a program to help cancer patients understand their fertility risks and get the right care. It included 434 women aged 15-55 with a new cancer diagnosis. The program aimed to connect them with specialists for pregnancy planning or fertility preservation based on …

This study collects blood, urine, and tissue samples from 330 adults with advanced lung or head and neck cancer to improve precision medicine. Researchers will analyze genetic changes in these samples and grow some tumors in mice to compare DNA. The goal is to refine liquid biops…

This study tests a web-based tool called REFLECT, designed to help adolescent and young adult cancer patients learn about fertility and genetic risks for future children. Sixteen participants who have had cancer care at Moffitt Cancer Center will use the tool and rate how easy an…

This study explores how cancer patients feel and what they do when they learn about extra genetic findings from their tumor tests. Researchers want to understand how patients decide to share this information with their family members. About 495 adults with solid tumors are taking…

This early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…

This study aimed to test a new device that rotates patients horizontally to take CT images for guiding radiation therapy in cancer patients. It was designed for adults with certain cancers, but the trial was withdrawn before enrolling anyone. The goal was to see if the images wer…

This study compares how a single bout of exercise changes immune cells and inflammation in cancer patients undergoing chemotherapy and in healthy people of the same age. Researchers will measure natural killer cells and other immune markers before and after exercise. The goal is …

This registry follows up to 75,000 cancer patients treated with proton or standard X-ray radiation at Loma Linda University Medical Center, some since 1990. The goal is to track long-term outcomes like disease-free survival and local recurrence to learn which radiation approaches…

This study looks at medical records of 50 cancer patients who say cannabis helped stop their tumor from growing or shrank it. Researchers want to see if there is real evidence behind these claims. The goal is to gather information, not to test a new treatment.

This early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or tr…

This study looks at different ways to reach out to African American patients and their doctors to see if it helps more of them join early phase cancer treatment trials. About 134 people will take part. The goal is to find better methods to make cancer research more inclusive.

This study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…

This study explores whether wearable devices, like smartwatches, can help monitor symptoms in cancer survivors. Twenty participants will wear a sensor-packed device that tracks temperature, heart rate, sleep, and activity. Researchers will see how many people agree to use the wea…

This study looks at whether the standard blood test given to pregnant women to screen for fetal conditions can also detect signs of cancer in the mother. Researchers will analyze DNA from 300 pregnant women with known or newly diagnosed cancer to identify specific chromosomal pat…

This study looks at whether a special health assessment for older adults with cancer can help doctors predict and reduce serious side effects from chemotherapy. About 600 patients with solid tumors will be evaluated before starting treatment. The goal is to improve care and quali…

This study looks at whether older adults with cancer can use computer surveys (like on a tablet or computer) to answer health questions. Researchers want to see if these digital tools are easy to use, reliable, and give the same results as paper surveys. About 100 people aged 65 …

This study tests whether personalized telehealth coaching can help young adult cancer survivors become more physically active and improve their diet. Researchers are enrolling 374 survivors aged 18-54 who are not very active. Participants receive one-on-one sessions with a clinic…

This study looks at whether training and support can help cancer clinics give special check-ups (called geriatric assessments) to patients aged 65 and older who are starting a new cancer treatment. These check-ups help find and address health issues, support needs, and daily life…

This study compares a new total body PET scanner (Omni TB) with conventional PET in 25 adult cancer patients. The new scanner can image the whole body at once with higher sensitivity, potentially allowing shorter scan times and lower radiation doses. Researchers will assess wheth…

This long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…

This study aims to create a more accurate way to measure depression in older adults who have or had cancer. Researchers will interview patients and test a new questionnaire designed specifically for this group. The goal is to improve how doctors identify and treat depression in o…

This study tests whether a geriatric assessment tool—looking at thinking, memory, daily activities, and emotional well-being—can predict serious side effects from chemotherapy in older adults with cancer. Over 1,000 patients completed questionnaires and cognitive tests before and…

This study looks at how people with chronic cancer pain take their long-acting opioid medications. The goal is to learn from their experiences and develop a better way to manage cancer pain. About 150 adults who are prescribed long-acting opioids for cancer pain will participate.…

This study looks at how well the body of women with early triple-negative breast cancer can switch between burning fat and sugar for energy—a trait called metabolic flexibility. Researchers will test if different types of exercise (moderate cardio, high-intensity cardio, or stren…

This study looks at whether certain blood cell counts and tumor-infiltrating lymphocytes can help predict if triple negative breast cancer will come back. Researchers will collect blood samples from 90 women after radiation and at the time of any first recurrence. The goal is to …

This study tests whether a wearable skin sensor can tell the difference between mild, moderate, and severe pain in 37 adults with cancer or COPD. Participants wear the device for up to a week and report their pain levels. The goal is to create an algorithm that alerts caregivers …

This study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…

This study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…

This study is collecting blood, saliva, and health information from 2,100 Black and White cancer patients who are receiving immunotherapy (drugs that help the immune system fight cancer). The goal is to see if there are differences in side effects and how well the treatment works…

This study looks at whether combining genetic tests, regular drug level checks, and careful medication reviews can help doctors prescribe the right drugs and avoid harmful side effects. It involves 450 adults with cancer and children with chronic inflammatory diseases. The goal i…

This study tests a communication method to help cancer patients and the general public learn about clinical trials and make informed decisions about joining. About 581 participants will receive information to increase their awareness and positive attitudes toward trials. The goal…

This study tests a new way to monitor proton therapy for solid tumors. A full-digital PET scanner tracks the proton beam's path and dose in real time. Thirty patients scheduled for proton therapy will participate. The goal is to improve treatment accuracy by seeing exactly where …

This study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.

This study was designed to see if a 14-day course of the drug Anakinra could change the immune environment around early-stage triple-negative or ER-low breast tumors. It was planned for people with small, early-stage tumors who were not scheduled for chemotherapy before surgery. …

This study is testing a new radiation technique that uses real-time MRI scans to target cancer more precisely. About 377 adult cancer patients will receive this treatment and have extra scans and quality-of-life surveys. The goal is to see if this approach improves tumor control …

This study looks at whether it's possible to track memory and thinking changes in adults aged 65 and older who are starting a new type of cancer treatment called immune checkpoint inhibitors. Thirty participants will take simple memory and concentration tests every six weeks for …

This study takes tumor tissue from 50 women with invasive breast cancer and grows mini 3D versions called organoids in the lab. These organoids are used to collect tiny particles called extracellular vesicles, which naturally seek out tumor cells. The goal is to use these particl…

This study looks at why some adults with advanced cancer are afraid to take opioids for pain, even when prescribed. Researchers will survey 50 patients to measure how fear, anxiety, and depression affect pain levels and medication use. The goal is to identify barriers so that pai…

This study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …

This pilot study is testing whether a personalized blood test that looks for leftover tumor DNA can help doctors make better treatment decisions for people with early-stage breast cancer. About 34 participants with triple-negative or HER2-positive breast cancer will receive chemo…

This study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…

This study looks at a new method for giving the cancer drug vincristine to infants and young children. The goal is to see if this new way of calculating the dose leads to similar drug levels in the blood as the standard method used in older children. About 83 children up to 12 ye…

This study looks at how doctors and nurses in radiation oncology used telehealth instead of in-person visits during the COVID-19 pandemic. Researchers will survey 1,000 healthcare providers at Duke Cancer Center to understand their experiences and challenges. They will also track…

This study tests whether an educational video can help adults with serious cancer understand and use palliative care. 172 participants will either receive standard care plus brochures, or standard care plus a tailored video and extra materials. Researchers will track knowledge, a…

This observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…

This study looks at how photobiomodulation (a type of light therapy) affects mouth sores and other oral symptoms in patients receiving a stem cell transplant. Researchers will track pain, taste changes, and dry mouth in about 6 patients. The goal is to gather information to impro…

This study looks at whether a special team of doctors and scientists (a genomic tumor board) can help more patients with advanced solid tumors get treatments that match their cancer's genetic makeup. About 1,284 patients will take part. The goal is to see if this team approach le…

This study was designed to look back at medical records of people in Picardy, France, who were diagnosed with both lymphoma and another cancer within six months between 2007 and 2012. The goal was to see if these cases were more common than expected and to describe patient charac…

This study looks at whether measuring certain inflammatory proteins (cytokines) in the blood during radiotherapy can help predict which triple-negative breast cancer patients are likely to have their cancer come back. Researchers will take blood samples from 15 women before and d…

This study looks at how the COVID-19 pandemic changed the number of new cancer cases in Bavaria, Germany. Researchers analyzed data from 438,000 adults diagnosed with cancer between 2018 and 2023 to see if certain regions or cancer types were more affected. The goal is to underst…

This study looks at financial problems (called 'financial toxicity') in young adults aged 18-39 who have finished cancer treatment. Researchers will survey 300 participants to measure money stress during and after therapy, and find out what factors make it worse. The goal is to l…

This study looks at how mind-body therapies—like mindfulness, laughter yoga, and art therapy—affect the quality of life and emotional distress of 150 cancer patients. Participants will fill out questionnaires before and after an 8-week program. The goal is to see if these therapi…

This study uses stem cells made from patients' own cells to understand why some people develop severe heart or lung side effects from certain chemotherapy drugs. Researchers will compare cells from patients who had extreme toxicity to those who did not. The goal is to uncover the…

This trial was designed to test whether adding aspirin to the immunotherapy drug avelumab could help the immune system fight triple-negative breast cancer. Participants would have received either avelumab alone or with aspirin for about 18 days, with biopsies and blood tests to m…

This study looks at whether a set of proteins in the blood can predict if triple-negative breast cancer will come back after treatment. Researchers will follow 90 women and test their blood at several time points. The goal is to find a simple way to identify patients who need clo…

This study looks at whether a genetic test (BRCA1-like) can help doctors choose the best first chemotherapy for people with advanced triple-negative breast cancer. About 304 participants will receive either carboplatin-cyclophosphamide or paclitaxel, with or without the immunothe…

This study is testing an online questionnaire called CHAMP that older adults with cancer can fill out before their doctor's visit. The tool asks about daily function, memory, mood, and support to help doctors tailor cancer treatment. Researchers want to see if the tool is easy to…

This study looks at whether certain inherited gene changes (EGFR mutations) increase the risk of lung cancer, especially in people who never smoked. Researchers collect saliva from cancer patients with a specific tumor mutation (T790M) to find these inherited changes. They also o…

This study looks at how the diversity of bacteria in the gut might affect how well immunotherapy works in people with solid tumors. Researchers will collect stool and blood samples from 70 cancer patients starting immunotherapy to track changes in gut bacteria and immune markers.…

This study follows 196 women aged 11-35 who are receiving chemotherapy for cancer. Researchers measure hormone levels and ovarian follicles before, during, and after treatment to see how the ovaries are affected. The goal is to better understand the risk of early menopause and fe…

This study looks at how well cancer patients respond to common vaccines like flu, COVID-19, and shingles. Researchers will measure antibody levels before and after vaccination in 250 adults with cancer. The goal is to understand immune responses in this group, not to test a new t…

This study looks at whether a blood test (liquid biopsy) can find cancer mutations as well as the standard tissue biopsy. Researchers will compare the two methods in 1,500 advanced cancer patients to see if the blood test helps doctors choose better treatments and saves money. Th…

This study was designed to see if a new monitoring algorithm could detect early signs of ovarian damage in women and girls who had cancer treatment. Researchers planned to compare a group using the new algorithm with a group that received standard care. However, the study was wit…

This study is checking if two substances in the blood, called IGF-1 and IGF-1Ec, are linked to how much cancer is in the body. Researchers will measure these levels in 100 adults with solid tumors and compare them to tumor size, stage, and spread. The goal is to see if these mark…